The Efficacy and Safety of the Combination Therapy With GLP-1 Receptor Agonists and SGLT-2 Inhibitors in Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis

The Efficacy and Safety of the Combination Therapy With GLP-1 Receptor Agonists and SGLT-2 Inhibitors in Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis

Aims: Glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors play a key role in the treatment of type 2 diabetes mellitus. This meta-analysis aims to evaluate the efficacy and safety of their combination, emphatically focusing on the effects of treatment duration an...

Full description

Bibliographic Details
Main Authors:	Chen Li, Jie Luo, Mingyan Jiang, Keke Wang
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-02-01
Series:	Frontiers in Pharmacology
Subjects:	glucagon-like peptide-1 receptor agonists sodium-glucose co-transporter-2 inhibitors combination therapy type 2 diabetes mellitus meta-analysis
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2022.838277/full

Similar Items

Combining glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) in patients with type 2 diabetes mellitus (T2DM)
by: Pierre Gourdy, et al.
Published: (2023-04-01)

Effectiveness and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in type 2 diabetes: an Italian cohort study
by: Marta Baviera, et al.
Published: (2022-08-01)

Anti-Inflammation and Anti-Oxidation: The Key to Unlocking the Cardiovascular Potential of SGLT2 Inhibitors and GLP1 Receptor Agonists
by: Veronika A. Myasoedova, et al.
Published: (2023-12-01)

Substantially different findings concerning the cardiovascular and cerebrovascular effectiveness of GLP1RAs vs. SGLT2is
by: Lixin Du, et al.
Published: (2022-10-01)

Cardiorenal and other diabetes related outcomes with SGLT-2 inhibitors compared to GLP-1 receptor agonists in type 2 diabetes: nationwide observational study
by: Moa Lugner, et al.
Published: (2021-03-01)

Influence of the combination of SGLT2 inhibitors and GLP-1 receptor agonists on eGFR decline in type 2 diabetes: post-hoc analysis of RECAP study
by: Yoshimi Muta, et al.
Published: (2024-03-01)

Effects of SGLT2 Inhibitors and GLP-1 Receptor Agonists on Renin-Angiotensin-Aldosterone System
by: Soraya Puglisi, et al.
Published: (2021-10-01)

Will GLP-1 Analogues and SGLT-2 Inhibitors Become New Game Changers for Diabetic Retinopathy?
by: Katarzyna Wołos-Kłosowicz, et al.
Published: (2022-10-01)

Characteristics predicting the efficacy of SGLT-2 inhibitors versus GLP-1 receptor agonists on major adverse cardiovascular events in type 2 diabetes mellitus: a meta-analysis study
by: Minji Sohn, et al.
Published: (2023-06-01)

Cardiovascular outcomes with SGLT2 inhibitors versus DPP4 inhibitors and GLP-1 receptor agonists in patients with heart failure with reduced and preserved ejection fraction
by: Jimmy Gonzalez, et al.
Published: (2023-03-01)

Impact of chronic GLP-1 RA and SGLT-2I therapy on in-hospital outcome of diabetic patients with acute myocardial infarction
by: Filippo Trombara, et al.
Published: (2023-02-01)

Inflammation and Oxidative Stress in Diabetic Kidney Disease: The Targets for SGLT2 Inhibitors and GLP-1 Receptor Agonists
by: Agata Winiarska, et al.
Published: (2021-10-01)

Making a case for the combined use of SGLT2 inhibitors and GLP1 receptor agonists for cardiorenal protection
by: Vikas S. Sridhar, et al.
Published: (2020-09-01)

Glucagon-Like Peptide-1 Receptor Agonists Added to Sodium-Glucose Cotransporter 2 Inhibitors in Type 2 Diabetes: A Historical Cohort Study Using the Diabetes Study From the Center of Tokyo Women's Medical University (DIACET)
by: Tetsuya Babazono, et al.
Published: (2023-11-01)

A practical review of diabetes mellitus type 2 treatment in primary care
by: Call Justin T., et al.
Published: (2022-03-01)

Combination of basal insulin and GLP-1 receptor agonist: is this the end of basal insulin alone in the treatment of type 2 diabetes?
by: Rodrigo Oliveira Moreira, et al.
Published: (2018-04-01)

Future Perspectives on GLP-1 Receptor Agonists and GLP-1/glucagon Receptor Co-agonists in the Treatment of NAFLD
by: Marta Seghieri, et al.
Published: (2018-11-01)

The advisory board resolution on the use of sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists in type 2 diabetes
by: M. B. Antsiferov, et al.
Published: (2023-05-01)

The prescribing pattern of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in patient with type two diabetes mellitus: A two-center retrospective cross-sectional study
by: Ghazwa B. Korayem, et al.
Published: (2022-10-01)

Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity
by: Baptist Gallwitz
Published: (2022-10-01)

Real-world effectiveness of GLP-1 receptor agonist-based treatment strategies on “time in range” in patients with type 2 diabetes
by: Yongru Chen, et al.
Published: (2024-03-01)

Long-acting agonists of human and rodent GLP-2 receptors for studies of the physiology and pharmacological potential of the GLP-2 system
by: Sarina Gadgaard, et al.
Published: (2023-04-01)

Insulin–glucagon‐like peptide‐1 receptor agonist relay and glucagon‐like peptide‐1 receptor agonist first regimens in individuals with type 2 diabetes: A randomized, open‐label trial study
by: Yumie Takeshita, et al.
Published: (2022-06-01)

Acute Low-Intensity Treadmill Running Upregulates the Expression of Intestinal Glucose Transporters via GLP-2 in Mice
by: Kai Aoki, et al.
Published: (2021-05-01)

GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art
by: Michael A. Nauck, et al.
Published: (2021-04-01)

Effects of GLP-1 receptor agonists on arrhythmias and its subtypes in patients with type 2 diabetes: A systematic review and meta-analysis
by: Jinjing Wei, et al.
Published: (2022-08-01)

A potentially serious adverse effect of GLP-1 receptor agonists
by: Jinmiao Lu, et al.
Published: (2023-05-01)

First-line treatment with sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists in type 2 diabetic population at low risk of cardiovascular disease: a meta-analysis
by: Rui Deng, et al.
Published: (2024-01-01)

Effect of Hemoglobin A1c Reduction or Weight Reduction on Blood Pressure in Glucagon‐Like Peptide‐1 Receptor Agonist and Sodium‐Glucose Cotransporter‐2 Inhibitor Treatment in Type 2 Diabetes Mellitus: A Meta‐Analysis
by: Mengdie Hu, et al.
Published: (2020-04-01)

GLP-1 Receptor Agonists and Kidney Protection
by: Eulalia Valentina Greco, et al.
Published: (2019-05-01)

An integrated approach for obesity management: the effectiveness of glucagon-like peptide 1 agonist and life-style interventions for obesity management
by: A.V. Dinets, et al.
Published: (2022-05-01)

Clinical Efficacy of Sodium-Glucose Cotransporter 2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy in Type 2 Diabetes Mellitus: Real-World Study
by: Hwi Seung Kim, et al.
Published: (2022-07-01)

Effects of Glucagon‐Like Peptide‐1 Receptor Agonists, Sodium‐Glucose Cotransporter‐2 Inhibitors, and Their Combination on Endothelial Glycocalyx, Arterial Function, and Myocardial Work Index in Patients With Type 2 Diabetes Mellitus After 12‐Month Treatment
by: Ignatios Ikonomidis, et al.
Published: (2020-05-01)

A systematic review of the safety of tirzepatide-a new dual GLP1 and GIP agonist - is its safety profile acceptable?
by: Zhuqing Meng, et al.
Published: (2023-03-01)

Antidiabetic Molecule Efficacy in Patients with Type 2 Diabetes Mellitus—A Real-Life Clinical Practice Study
by: Teodor Salmen, et al.
Published: (2023-09-01)

Editorial: Reviews and Novel Clinical Perspectives on Semaglutide: A GLP-1 Receptor Agonist With Both Injectable and Oral Formulations
by: Juris J. Meier, et al.
Published: (2021-09-01)

A meta-analysis evaluating indirectly GLP-1 receptor agonists and arrhythmias in patients with type 2 diabetes and myocardial infarction
by: Zhijie Liu, et al.
Published: (2022-10-01)

Effectiveness and safety of the combination of sodium–glucose transport protein 2 inhibitors and glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of observational studies
by: Aftab Ahmad, et al.
Published: (2024-03-01)

Risks of stroke, its subtypes and atrial fibrillation associated with glucagon-like peptide 1 receptor agonists versus sodium-glucose cotransporter 2 inhibitors: a real-world population-based cohort study in Hong Kong
by: David Tak Wai Lui, et al.
Published: (2023-02-01)

SGLT2 Inhibitors vs. GLP-1 Agonists to Treat the Heart, the Kidneys and the Brain
by: Bartosz Rolek, et al.
Published: (2023-07-01)